DEVELOPMENT AND PROPERTIES OF NEUTRALIZING MONOCLONAL ANTIBODIES FOR FUSION PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS

Cover Page


Cite item

Full Text

Abstract

Introduction. Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in infants and the elderly. The absence of a wide range of therapeutic drugs and vaccines indicates to the high relevance of the development of new effective drugs for the prevention and treatment of RSV infections. Purpose: to obtain highly active and specific monoclonal antibodies (MAbs) capable of detecting RSV in infected cells and neutralizing the infectious activity of the virus in vitro. Material and methods. RSV reference strains of group A 2 subgroups (A2 and Long) were propagated in HEp-2 and MA-104 cell lines, respectively. Mice were immunized with purified RSV A2 virus. MAbs were obtained using hybridoma technology. Results. A panel of 6 MAbs reacting with RSV strains А2 and Long has been obtained. Four MAbs were IgG (IgG2a or IgG2b subtype), two MAbs were IgM. All MAbs reacted with RSV F-protein in immunochemical tests. The MAbs actively reacted with RSV in ELISA, in immufluorescence and peroxidase staining of infected cells, and in immunodot test. Five out of 6 MAbs neutralized of RSV in cell culture. Different properties of MAbs suggest that they target different antigenic sites of F-protein. Discussion. Comparative analysis suggests that the obtained MAbs can be used for the development of diagnostic preparations, for RSV detection in clinical materials and confirmation of infection etiology by rapid culture method. Conclusion. High activity and specificity of MAbs indicate that they can serve as a basis for development vaccines and preventive medicines.

About the authors

A. A. Kushch

Ivanovsky Institute of Virology «National Research Centre for Epidemiology and Microbiology named honorary academician NF Gamaleya»

Author for correspondence.
Email: vitallku@mail.ru
Russian Federation

R. R. Klimova

Ivanovsky Institute of Virology «National Research Centre for Epidemiology and Microbiology named honorary academician NF Gamaleya»

Email: noemail@neicon.ru
Russian Federation

N. E. Fedorova

Ivanovsky Institute of Virology «National Research Centre for Epidemiology and Microbiology named honorary academician NF Gamaleya»

Email: noemail@neicon.ru
Russian Federation

O. V. Masalova

Ivanovsky Institute of Virology «National Research Centre for Epidemiology and Microbiology named honorary academician NF Gamaleya»

Email: noemail@neicon.ru
Russian Federation

A. A. Niconova

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

E. I. Lesnova

Ivanovsky Institute of Virology «National Research Centre for Epidemiology and Microbiology named honorary academician NF Gamaleya»

Email: noemail@neicon.ru
Russian Federation

E. D. Momotyuk

Ivanovsky Institute of Virology «National Research Centre for Epidemiology and Microbiology named honorary academician NF Gamaleya»

Email: noemail@neicon.ru
Russian Federation

N. A. Demidova

Ivanovsky Institute of Virology «National Research Centre for Epidemiology and Microbiology named honorary academician NF Gamaleya»

Email: noemail@neicon.ru
Russian Federation

T. G. Samartseva

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

V. V. Zverev

Mechnikov Research Institute of Vaccines and Sera

Email: noemail@neicon.ru
Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2019 Kushch A.A., Klimova R.R., Fedorova N.E., Masalova O.V., Niconova A.A., Lesnova E.I., Momotyuk E.D., Demidova N.A., Samartseva T.G., Zverev V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies